C3 GLOMERULOPATHY
Clinical trials for C3 GLOMERULOPATHY explained in plain language.
Never miss a new study
Get alerted when new C3 GLOMERULOPATHY trials appear
Sign up with your email to follow new studies for C3 GLOMERULOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug tested for rare kidney conditions
Disease control CompletedThis early-stage study tested the safety and effects of an experimental drug called ARO-C3. It involved 62 healthy volunteers and patients with rare kidney diseases (C3G and IgAN). The goal was to see how the body processes the drug and determine safe dose levels for future resea…
Matched conditions: C3 GLOMERULOPATHY
Phase: PHASE1, PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Breakthrough injection shows promise for devastating kidney conditions
Disease control CompletedThis Phase 3 study tested whether pegcetacoplan injections could help people with rare kidney diseases called C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN). The trial involved 124 participants who received either the actual drug or p…
Matched conditions: C3 GLOMERULOPATHY
Phase: PHASE3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC